A control group is the arm of a study that does not receive the intervention being tested, or receives a defined comparator instead of it. Its purpose is to supply the counterfactual: what would have happened to these same kinds of participants or units without the intervention. Without that comparison, an observed change after an intervention cannot be safely attributed to the intervention itself, because several other explanations compete for the same evidence — the passage of time, participants’ expectations (the placebo response), regression to the mean, and the natural course of a condition that may have improved or worsened on its own. A control group holds those alternative explanations constant across both arms so that the only systematic difference left between them is the intervention.
Why a Study Needs a Control Group
Single-arm, before-after observation (measure a group, apply an intervention, measure again) cannot distinguish an intervention effect from four things that happen anyway: regression to the mean (extreme baseline values naturally drift toward average on remeasurement, independent of treatment), natural history (many conditions improve, worsen, or fluctuate on their own), secular trends (the outside world changes during the study period), and the placebo/expectation effect (participants and observers respond to the experience of receiving something, not only to its active content). A properly constructed control group experiences the same passage of time, the same measurement process, and, where blinding is used, the same expectation of receiving an active intervention — so any remaining difference in outcomes is attributable to the intervention rather than to these confounds.
Types of Control Groups
Not every study needs the same kind of control. The choice depends on whether an effective intervention already exists, on ethical constraints, and on what the study is trying to show.
- No-treatment control — participants receive nothing at all, only the same assessments as the intervention group. Appropriate when the intervention has no meaningful placebo (e.g. a behavioral or educational program with nothing plausible to mimic) or when blinding is not feasible or not required.
- Placebo control — participants receive an inert or sham intervention indistinguishable from the real one, isolating the intervention’s specific effect from the act of receiving care and the expectation of benefit. See Placebo-Controlled Study Design for the ethical and design detail behind this option.
- Active (standard-of-care) comparator — participants receive the best currently proven intervention rather than nothing or placebo. Required whenever an effective, proven intervention already exists for the condition under study (see Ethics below); the trial then asks whether the new intervention is superior, non-inferior, or equivalent, not merely whether it beats doing nothing.
- Waitlist control — participants are assigned to receive the intervention later, and outcomes are compared while the waitlisted group is still waiting. Common in behavioral, educational, and psychological research where withholding an active comparator indefinitely would be impractical, but it raises its own ethical issue: participants with a genuinely effective treatment available are asked to go without it for the study’s duration, so it is defensible mainly when the intervention is scarce, novel, or not otherwise available to this population, and the wait is short and clearly bounded.
- Historical (external) control — outcomes in the treated group are compared against outcomes recorded in an earlier cohort or from published literature rather than a concurrently randomized group. Used mainly in rare diseases and some oncology trials where a concurrent control is infeasible or unethical, but it forfeits randomization’s protection against confounding: historical cohorts differ in unmeasured ways (era of care, diagnostic criteria, supportive treatment) that can masquerade as an intervention effect.
- Dose-comparison control — two or more doses of the same intervention are compared against each other rather than against placebo or no treatment, used to characterize a dose-response relationship or to select a dose for further testing.
- Sham control — used for procedural, device, or surgical interventions: participants undergo a comparable procedure (e.g. incision without the device activated, a mock scanning session) so that the ritual, attention, and expectation of a procedure are matched between arms. Sham controls raise sharper ethical questions than pharmacological placebo because the sham procedure itself can carry real risk.
This taxonomy follows the structure used in ICH E10 (Choice of Control Group and Related Issues in Clinical Trials), the internationally harmonized guideline jointly adopted by FDA, EMA, and Japan’s PMDA, which formally recognizes placebo, no-treatment, dose-response, active, and external/historical concurrent control categories, plus the use of multiple control groups in a single trial.
The Ethics of Choosing a Control Group
The choice of comparator is not only a methodological decision; it determines what participants in the control arm receive, or go without, for the duration of the study. The World Medical Association’s Declaration of Helsinki (most recently revised October 2024), the foundational international statement of research ethics for studies involving human participants, addresses this directly in its placebo provision (paragraph 33): a new intervention’s benefits, risks, burdens, and effectiveness must generally be tested against those of the best proven intervention(s), except that placebo or no-intervention control is acceptable when either (a) no proven intervention exists for the condition under study, or (b) there are compelling and scientifically sound methodological reasons for using placebo or no intervention to determine the efficacy or safety of the new intervention, and participants who receive placebo or no intervention will not be subject to additional risk of serious or irreversible harm as a result of not receiving the best proven intervention. The Declaration explicitly warns that extreme care must be taken to avoid abuse of this option.
This is closely tied to clinical equipoise: genuine uncertainty, within the expert medical community, about which of two or more interventions (including a control condition) is actually better. A trial is ethically justifiable only while equipoise holds; once evidence accumulates that one arm is clearly superior or inferior, continuing to randomize participants to the disadvantaged arm becomes difficult to justify, which is why trials with a proven-harm or proven-benefit signal are typically stopped early on the recommendation of a data safety monitoring board.
Waitlist controls deserve the same scrutiny for a different reason: when an effective treatment exists and is being withheld from the control arm for the study’s duration, an ethics review needs to weigh the value of the comparison against the cost to participants of delayed access, the length of the wait, and whether standard care is still available to the waitlisted group in the meantime.
Randomization and Allocation Concealment
How participants end up in the control group versus the intervention group matters as much as what the control group receives. Randomization assigns participants to arms by a chance process (simple, block, stratified, or minimization-based) so that known and unknown confounders are, on average, balanced between groups — this is what allows a difference in outcomes to be attributed to the intervention rather than to systematic differences in who ended up in each arm. Allocation concealment is a distinct, easily conflated safeguard: it means the sequence’s implementation is hidden from whoever enrolls participants until the moment of assignment, preventing enrollers from steering particular participants toward or away from a given arm. Randomization and allocation concealment address selection bias at the point of enrollment; blinding, covered next, addresses a different bias entirely, arising after assignment.
Blinding
Blinding (masking) concerns who knows which arm a participant is in after randomization has occurred: the participant, the clinician or research staff delivering the intervention, and the outcome assessor can each be blinded independently, and a study is commonly described by how many of these roles are blinded (single-, double-, or triple-blind). Blinding guards against performance bias (participants or staff behaving differently based on known allocation) and detection bias (assessors rating outcomes differently based on known allocation), both of which are separate concerns from the selection bias randomization addresses. A placebo or sham control is what actually makes blinding possible in many trials — without an indistinguishable comparator, there is nothing to blind participants or assessors to. An open-label (unblinded) trial can still be a methodologically valid randomized study provided randomization and a control arm are both present; it simply carries a higher risk of performance and detection bias on subjective outcomes.
Control Groups Outside Clinical Trials
The logic of a control group is not specific to medicine; it is a general requirement of causal inference wherever an intervention’s effect needs to be isolated from everything else that could explain a change.
- Education — a classroom or cohort using a new teaching method or curriculum is compared against a classroom or cohort continuing with standard instruction, so that gains can be attributed to the method rather than to the school year’s general maturation or a particularly strong cohort.
- Psychology and behavioral science — an experimental condition (e.g. a specific stimulus, task, or therapeutic technique) is compared against a control condition that omits only the manipulation of interest, isolating that manipulation’s effect from general demand characteristics or the passage of time.
- Agriculture — a treated plot (new fertilizer, cultivar, or irrigation method) is compared against an untreated or standard-practice plot under the same field conditions, so that yield differences can be attributed to the treatment rather than to soil variation or weather across the growing season.
- Laboratory science — wet-lab experiments distinguish several specific control types: a negative control is expected to show no effect and confirms the assay isn’t producing false positives; a positive control is expected to show a known effect and confirms the assay is capable of detecting one; and a vehicle control receives only the solvent or carrier used to deliver a treatment (e.g. DMSO, saline), which distinguishes an effect caused by the active compound from one caused by the delivery vehicle itself.
When You Cannot Have a Control Group
A concurrent, randomized control group is not always available — because randomization is unethical or infeasible, because the exposure of interest is something researchers cannot assign, or because the intervention has already been rolled out. Several designs substitute for it, at a real cost in inferential strength:
- Observational designs (cohort, case-control, cross-sectional) compare groups that were never randomly assigned, so any observed association is vulnerable to confounding by the factors that led participants into one group rather than another — see Case-Control Study vs. Cohort Study and RCT vs. Observational Study for how the evidence strength differs.
- Single-arm trials with historical comparison compare outcomes in treated participants against a historical cohort’s outcomes rather than a concurrent control, common in rare-disease and some oncology research; the tradeoff is described under Historical control above.
- Natural experiments exploit a real-world event or policy change that assigns exposure to some units and not others as if by chance (e.g. a policy that takes effect on one side of an administrative boundary), approximating randomization without the researcher actually assigning it.
- Quasi-experimental designs use statistical strategies to approximate a control group where none exists: difference-in-differences compares the change over time in an exposed group against the change over time in an unexposed group, netting out shared trends; regression discontinuity compares units just above and just below an assignment threshold (e.g. a funding cutoff score), treating them as comparable near the cutoff; and interrupted time series compares the trend in an outcome before and after an intervention within the same population, using the pre-intervention trend as the counterfactual for what would have continued without it. See Experimental vs. Quasi-Experimental Design for a fuller comparison.
Every one of these substitutes trades some of a true control group’s protection against confounding for feasibility or ethics; findings from them generally support a weaker causal claim than a well-randomized controlled comparison, and should be reported and interpreted accordingly — see Correlation vs. Causation and Internal vs. External Validity.
Common Problems With Control Groups
- Contamination — control-arm participants are inadvertently exposed to the intervention (e.g. through informal contact with intervention-arm participants, or clinical staff applying elements of the new approach to everyone), diluting the measured difference between arms toward zero.
- Differential attrition — participants drop out of one arm at a different rate, or for different reasons, than the other. If dropout is related to the outcome (e.g. participants who aren’t responding leave the control arm disproportionately), the remaining groups are no longer comparable even though they started out randomized and balanced.
- Non-compliance and intention-to-treat vs. per-protocol analysis — not every participant assigned to an arm actually receives, or adheres to, what that arm specifies. Intention-to-treat (ITT) analysis keeps participants in the arm they were randomized to regardless of what they actually received, preserving randomization’s balance and generally giving a conservative, real-world estimate of effect; per-protocol analysis restricts the comparison to participants who adhered to their assigned arm as specified, which can better isolate the intervention’s efficacy under ideal conditions but reintroduces the selection bias randomization was meant to remove. See Intent-to-Treat vs. Per-Protocol Analysis for when each is reported.
- Unblinding — participants, staff, or assessors correctly guess the allocation (sometimes because a placebo has a distinguishable side-effect profile from the active drug), reintroducing the performance and detection biases blinding was meant to prevent.
Reporting the Control Group: CONSORT Expectations
For randomized trials, the CONSORT statement (Consolidated Standards of Reporting Trials, most recently updated to CONSORT 2025) sets the reporting bar for describing a comparator with enough precision that another team could replicate it: the Methods section of the checklist requires precise, replicable detail on the interventions delivered to each group, including the control/comparator condition, not only the experimental one, plus how and when they were administered. CONSORT’s flow diagram requires accounting for every participant randomized to the control arm through enrollment, allocation, follow-up, and analysis, and its items on randomization sequence generation and allocation concealment (distinct items, see Randomization above) apply to the control arm exactly as they do to the intervention arm. A manuscript that describes the experimental intervention in detail but the control condition only as “usual care” or “placebo” without specifying what that involved falls short of CONSORT’s expectations and makes the trial harder to interpret or replicate.
Frequently Asked Questions
What is the difference between a control group and a placebo group?
A placebo group is one specific type of control group — one that receives an inert or sham intervention designed to be indistinguishable from the real one. “Control group” is the broader category and also includes no-treatment, active-comparator, waitlist, historical, dose-comparison, and sham controls; which type is used depends on what’s ethical and methodologically appropriate for the specific study.
Can a study have more than one control group?
Yes. ICH E10 explicitly recognizes trials with multiple control groups, for example a placebo arm and an active-comparator arm in the same trial, which lets a study show both that a new intervention beats doing nothing and how it compares to the existing standard of care.
Why can’t every study use a randomized control group?
Randomization is sometimes unethical (withholding a known-effective treatment), infeasible (the exposure of interest, such as a lifestyle factor or policy, cannot be assigned by a researcher), or impossible because the intervention has already been implemented before the study began. In those cases researchers use observational designs, natural experiments, or quasi-experimental methods (difference-in-differences, regression discontinuity, interrupted time series) as substitutes, at a real cost in how confidently the result can be called causal.
What is the difference between a negative control and a positive control?
Both are laboratory-science terms rather than clinical-trial terms. A negative control is expected to produce no effect and confirms an assay isn’t generating false positives; a positive control is expected to produce a known effect and confirms the assay is actually capable of detecting a true effect when one is present.
Does a control group have to be blinded?
No. Blinding and having a control group are separate design features. A trial can have a control group without blinding anyone (an open-label trial), and blinding is easiest to achieve when the control is a placebo or sham indistinguishable from the active intervention — it is much harder, or impossible, to blind a no-treatment or waitlist control.
